Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications

Date published: 2021-03-05

Drugs and vaccines that have been authorized by Health Canada for use in relation to the COVID-19 pandemic are listed here.

In the list below, the entry for each authorized drug and vaccine includes the:

In the "authorization" column, there are 4 possible scenarios for each drug or vaccine:

List of authorized drugs, vaccines and expanded indications for COVID-19
Authorization holder Brand name, proper name or common name DIN, medicinal ingredient(s), strength, dosage form, route of administration Therapeutic area Control number Date of authorization or expanded indication Authorization or expanded indication
BioNTech Manufacturing GmbH Pfizer-BioNTech COVID-19 Vaccine
Tozinameran (mRNA vaccine, BNT162b2) suspension for injection
DIN 02509210 – 30 mcg/0.3 mL tozinameran, suspension, intramuscular administration Vaccines, for human use 244906 2020-12-09 Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Authorized with terms and conditions.
Gilead Sciences Canada Inc. Veklury
Remdesivir solution for injection

DIN 02502135 - 100 mg/20 mL remdesivir, solution, intravenous administration

DIN 02502143 - 100 mg/vial remdesivir, powder for solution, intravenous administration

Antivirals for systemic use, for human use 240551 2020-07-27 Food and Drug Regulations. Issued Notice of Compliance under the NOC/c Guidance.
Eli Lilly Canada Inc Bamlanivimab
Bamlanivimab solution for injection
DIN 02508176 - 700 mg/20 mL bamlanivimab, solution, intravenous administration Immune sera and immunoglobulins, for human use 244947 2020-11-20 Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Authorized with terms and conditions.
Moderna Therapeutics Inc COVID-19 Vaccine Moderna
mRNA-1273 SARS-CoV-2
suspension for injection
DIN 02510014 – 100 mcg/0.5 mL mRNA-1273 SARS-CoV-2, suspension, intramuscular administration Vaccines, for human use 244946 2020-12-23 Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Authorized with terms and conditions.
AstraZeneca Canada Inc AstraZeneca COVID-19 Vaccine
ChAdOx1-S (recombinant)
solution for injection

DIN 02510847 – 5x1010 VP/0.5 mL ChAdOx1-S (recombinant), 10-dose vial, solution, intramuscular administration

DIN 02511444 – 5x1010 VP/0.5 mL ChAdOx1-S (recombinant), 8-dose vial, solution, intramuscular administration

Vaccines, for human use 244627 2021-02-26 Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Authorized with terms and conditions.
Verity Pharmaceuticals Inc/Serum Institute of India (in partnership with AstraZeneca Canada Inc) Covishield
ChAdOx1-S (recombinant)
solution for injection
DIN 02512947 - 5x1010 VP/0.5 mL ChAdOx1-S (recombinant), 10-dose vial, solution, intramuscular administration Vaccines, for human use 248651 2021-02-26 Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Authorized with terms and conditions.
Janssen Inc Janssen COVID-19 Vaccine
AD26.COV2.S (recombinant)
suspension for injection
DIN 02513153 – 5x1010 VP/0.5 mL AD26.COV2.S (recombinant), suspension, intramuscular administration Vaccines, for human use 246758 2021-03-05 Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Authorized with terms and conditions.
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: